Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
| ▸ | LIPE | Q05469 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333263 | 0.88 | ENPP2 (0.67) | ENPP2LIPEHTR2CHTR2BSLC6A4 | |
| SCHEMBL29956447 | 0.88 | ENPP2 (0.67) | ENPP2LIPEHTR2CHTR2BSLC6A4 | |
| SCHEMBL5433420 | 0.83 | LIPE (0.68) | ENPP2LIPE | |
| SCHEMBL26616057 | 0.83 | LIPE (0.68) | ENPP2LIPEPTGER1MRGPRX4 | |
| SCHEMBL29953350 | 0.83 | LIPE (0.68) | ENPP2LIPE | |
| SCHEMBL5103313 | 0.81 | PTGER1 (0.63) | ENPP2LIPEPTGER1 | |
| SCHEMBL1954543 | 0.81 | LIPE (0.71) | ENPP2LIPEPTGER1MRGPRX4 | |
| SCHEMBL29953622 | 0.81 | LIPE (0.71) | ENPP2LIPEPTGER1MRGPRX4 | |
| SCHEMBL2557075 | 0.81 | LIPE (0.75) | ENPP2LIPE | |
| SCHEMBL1954388 | 0.80 | LIPE (0.64) | ENPP2LIPEMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446222-B2 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060235057-A1 | Phenyl compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1556330-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039753-A2 | PHENYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235057-A1 | Phenyl compounds | RXRB, CYP2C9, RXFP1 | ENPP2 1449/4885LIPE 3245/4885HTR2C 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.